NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd.  (“Biohaven” or the “Company”) (NYSE: BHVN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Biohaven and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 14, 2025, ...

Volatile biotech stock Biohaven (BHVN -19.41%) is prone to sharp movements both up and down. On Thursday, it had one of its down days, with its share price eroding by almost 20% on a development with a top regulator. That was on a day when stocks generally did well, as indicated by the S&P 500 (^GSPC 0.41%) landing in positive territory with a 0.4% rise. A regulatory extensionAfter market close on Wednesday, Biohaven divulged that the U.S. Food and Drug Administration's (FDA) Division of Neurology 1 is exte ...

Biohaven Ltd. BHVN shares plunged on Thursday after the Food and Drug Administration (FDA) unexpectedly delayed the review date for its rare-disease drug troriluzole.The Division of Neurology 1 within FDA’s Office of Neuroscience informed Biohaven that they are extending the PDUFA date for the troriluzole new drug application (NDA) for spinocerebellar ataxia (SCA) by three months to provide time for a full review of Biohaven’s recent submissions related to information requests from the FDA.If approved, tror ...

- Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. - Troriluzole has been granted Fast-Track, Orphan Drug Designation (ODD) and Priority Review from the FDA.- Troriluzole would be the first and only FDA-approved treatment for SCA, if approved.NEW HAVEN, Conn., May 14, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced that the Division of Neurology 1 within FDA's Office of Neuroscience informed th ...

UNITED STATES OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41477 Biohaven Ltd. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 (Exact name of registrant as specified in its charter) British Virgin Islands Not applicable (State or other jurisdiction of incorporation or o ...

Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments NEW HAVEN, Conn., May 12, 2025 /PRNewswire/ – Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life- changing therapies to treat a broad range of rare and common diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a review of recent accomplishments and antici ...

Shares of Biohaven (BHVN 5.04%) are surging on Monday. The company's stock was up about 8% as of midday trading and had climbed as much as 10% earlier in the day. The move comes as the S&P 500 traded mixed and the Nasdaq Composite drifted slightly higher.Shares of the clinical-stage biopharmaceutical company were rising after Biohaven announced a $600 million non-dilutive financing deal with Oberland Capital.A big cash infusionBiohaven revealed it has secured up to $600 million from the investment firm Ober ...

Core Viewpoint - Biohaven Ltd. has entered into a significant investment agreement with Oberland Capital Management for up to $600 million, aimed at supporting ongoing clinical trials and commercialization efforts for its product, troriluzole, targeting spinocerebellar ataxia (SCA) [1][2][3] Group 1: Investment Details - The agreement includes an initial funding of $250 million to be provided at closing on or before April 30, 2025 [1][6] - An additional $150 million is contingent upon FDA approval of troriluzole, with further funding of up to $200 million available for strategic acquisitions and related expenses [3][6] - The investment is structured as a Note Purchase Agreement (NPA) that is non-dilutive to existing shareholders [3][6] Group 2: Product and Market Potential - Troriluzole is a novel prodrug designed to modulate glutamate levels, which has potential applications in various diseases beyond SCA [5][8] - The investment will facilitate the advancement of Biohaven's pipeline, which includes five innovative platforms across immunology, neuroscience, and oncology [3][8] Group 3: Strategic Partnership - Oberland Capital expresses confidence in Biohaven's ability to address unmet needs in rare diseases and is committed to supporting the launch of troriluzole [3][9] - The partnership is expected to leverage Oberland's expertise in funding rare disease product launches, enhancing Biohaven's operational capabilities [3][9]

On Friday's news that Biohaven (BHVN -15.34%) withdrew its application for a top investigational drug from an important regulator, investors aggressively traded out of the stock. The clinical-stage biotech was one of the biggest decliners in its industry, exiting Friday with a share price decline of over 15%. This was during a session that was essentially bullish; the S&P 500 index closed 0.6% higher. Strategic withdrawalThat news came not from Biohaven itself, but from the European Medicines Agency (EMA, t ...

LOS ANGELES, April 15, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE: BHVN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Biohaven announced its financial results for Q4 and full year 2024 on March 3, 2025. ...